肿瘤微环境显像示踪剂研发的挑战
本文综述肿瘤微环境(TME)分子显像示踪剂研发全流程中的生物学、技术和方法学挑战,涵盖靶点选择、分子形式、放射性化学、临床前评价和数据分析各环节。文章指出低且动态的靶表达、亲和力与摩尔活度及受体占位的紧密耦合、标准体外实验适用性有限、体内模型复杂化及图像解读易错性等核心难题,并提出肽与工程抗体片段、阶梯式问题驱动流程、统一临床前模型及整合靶向理念等新兴解决方向。
要点
- TME显像示踪剂研发面临低且动态靶表达、亲和力与摩尔活度耦合等独特挑战。
- 标准体外实验适用性有限、体内模型复杂化及图像解读易错性增加研发难度。
- 肽与工程抗体片段、阶梯式评价流程和统一临床前模型是新兴解决方向。
核心结论
- TME显像示踪剂研发中的生物学与技术限制并非不可逾越的障碍,而是界定TME显像策略开发与解读的边界条件。
研究设计与样本
- 本文为综述,系统分析TME靶向放射性药物研发管线中靶点选择、分子形式选择、放射性化学、临床前评价和数据分析各环节的挑战。
主要发现
- TME显像面临低且动态的靶表达、示踪剂亲和力与摩尔活度及受体占位之间的紧密耦合、标准体外实验适用性有限、体内模型复杂度增加及图像解读与定量易错性升高等挑战。
- 免疫检查点与CD8⁺T细胞显像的早期临床成功凸显了TME显像策略的转化潜力。
临床怎么用
- TME显像策略的开发与解读需在生物学与技术边界条件内进行,并采用阶梯式、问题驱动的评价流程及整合靶向理念以衔接生物学相关性与技术可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular imaging of the tumor microenvironment (TME) has emerged as a powerful approach to non-invasively interrogate immune cell composition, activation state and functional dynamics, thereby addressing key limitations of biopsy-based biomarkers in immuno-oncology. Early clinical successes, particularly in immune checkpoint and CD8⁺ T-cell imaging, underscore the translational potential of this strategy. However, the development of robust and clinically relevant TME-targeted radiopharmaceuticals is confronted with a distinct set of biological, technical and methodological challenges that fundamentally differentiate it from classical tumor imaging. These include low and dynamic target expression, tight coupling between tracer affinity, molar activity and receptor occupancy, limited suitability of standard in vitro assays, increasing complexity of in vivo models, and heightened vulnerability to pitfalls in image interpretation and quantification.This review provides a comprehensive analysis of these challenges across the tracer development pipeline, spanning target selection, molecular format choice, radiochemistry, preclinical evaluation and data analysis. Rather than representing prohibitive obstacles, these limitations delineate the biological and technical boundary conditions within which TME imaging strategies must be developed and interpreted. Emerging solutions include the growing role of peptides and engineered antibody fragments, stepwise and question-driven evaluation workflows, harmonized preclinical models and integrated targeting concepts that align biological relevance with technical feasibility. Together, these considerations provide a framework for sustainable and translational progress in TME imaging.
引用
- Martin S, Wendlinger L, Koch H, et al. Challenges in tracer development for tumor microenvironment (TME) imaging. Eur J Nucl Med Mol Imaging. 2026. PMID: 41961275. doi:10.1007/s00259-026-07836-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。